Company Info

Failed to load

Monopteros Therapeutics

Drug Discovery & Development

Overview

Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset, MPT-0118, is undergoing a Phase 1/1b clinical trial to investigate reprogramming regulatory T cells in solid tumors.

Monopteros operates under Series-A funding from Medicxi and holds exclusive patent licenses from the Massachusetts General Hospital and Helmholtz Zentrum München.

Failed to load

Contributions

Contributors

Contributions

1 Contributions1 / 1

Clinical Trials